This Week in HIV Research: This Is Your Brain on (HIV) Drugs

This Week in HIV Research: This Is Your Brain on (HIV) Drugs

1 of 5
Next >

This week in our brief exploration of four under-the-radar, recently published studies on HIV, we learn about:

  • A massive, long-term study comparing relative rates of AIDS-defining neurological conditions among people taking efavirenz (Sustiva, Stocrin) vs. some of the other popular NRTIs.
  • Early, promising results from an HIV-specific study involving the smoking cessation aid varenicline (Chantix).
  • Signs that women on pre-exposure prophylaxis (PrEP) will often keep on taking the regimen even when their HIV-positive partners begin antiretroviral therapy.
  • Strong hints that stigma leads many HIV-positive Ugandans to avoid admitting, even to researchers, that they're taking antiretrovirals.

Read on for a closer look. To beat HIV, you have to follow the science!

Image Credit: Ralwel for iStock via Thinkstock

This week in our brief exploration of four under-the-radar, recently published studies on HIV, we learn about:

  • A massive, long-term study comparing relative rates of AIDS-defining neurological conditions among people taking efavirenz (Sustiva, Stocrin) vs. some of the other popular NRTIs.
  • Early, promising results from an HIV-specific study involving the smoking cessation aid varenicline (Chantix).
  • Signs that women on pre-exposure prophylaxis (PrEP) will often keep on taking the regimen even when their HIV-positive partners begin antiretroviral therapy.
  • Strong hints that stigma leads many HIV-positive Ugandans to avoid admitting, even to researchers, that they're taking antiretrovirals.

Read on for a closer look. To beat HIV, you have to follow the science!

Image Credit: Ralwel for iStock via Thinkstock